Massachusetts Financial Services Co. MA Has $1.67 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Massachusetts Financial Services Co. MA decreased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,816 shares of the company’s stock after selling 1,618 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Kiniksa Pharmaceuticals were worth $1,670,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after acquiring an additional 382,539 shares during the period. Rubric Capital Management LP grew its stake in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares during the period. Dimensional Fund Advisors LP increased its holdings in Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals in the third quarter valued at about $2,438,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 40.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock worth $8,098,000 after buying an additional 92,985 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on KNSA shares. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Evercore ISI boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $22.32 on Thursday. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -157.56 and a beta of 0.35. The business’s 50-day moving average price is $24.16 and its two-hundred day moving average price is $22.93. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $15.52 and a 1 year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same period in the prior year, the business posted ($0.20) EPS. The firm’s quarterly revenue was up 67.4% compared to the same quarter last year. Sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. This represents a 53.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 95,192 shares of company stock valued at $2,479,390 over the last 90 days. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.